Dr. Lwin On The Results Of The Leap-005 Trial In Advanced Solid Tumors

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

European Society for Medical Oncology (ESMO)

LBA41 - LEAP-005: Phase II study of lenvatinib plus pembrolizumab

Promising results from the gastric cancer cohort of LEAP-005

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

LEAP-011: exploring first-line pembrolizumab + lenvatinib for advanced urothelial carcinoma

Phase I/II trial of dendrimer-enhanced SN38 in patients with advanced solid tumors

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progressi...

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma

Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor...

Advances in intratumoral therapy and an update on the BDB001-102 trial

Clinical Trial: YL201 for Solid Tumors (NCT05434234)

Power Life Sciences

Bemarituzumab in solid tumors

Zarnie Lwin, MBBS, FRACP, speculates on future development of combo pembrolizumab + lenvatinib

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Targeted Oncology

The future of cellular therapies for solid tumors

Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors

PeerView Oncology

Clinical Trial: BGB-24714 for Solid Tumors (NCT05381909)

Power Life Sciences